Mikhail N. Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes. World J Diabetes 2014; 5(6): 854-859 [PMID: 25512787 DOI: 10.4239/wjd.v5.i6.854]
Corresponding Author of This Article
Nasser Mikhail, MD, MSc, Department of Medicine, Endocrine Division, OliveView-UCLA Medical Center, 14445 Olive View Dr, Sylmar, CA 91342, United States. nmikhail@dhs.lacounty.gov
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/